retatrutide type 2 diabetes phase 2 results 2024 2025 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished 🚨Breaking: Retatrutide's first Phase 3

It's important to note that while NR is generally recognized as a dietary supplement in the US, the FDA has indicated that NMN is excluded from the dietary supplement definition

Despite media narratives that often frame GLP-1 drugs as empowering, over half of women (52%) and more than a third of men (37%) believe users are judged negatively, seen as taking the easy way out

So, its so hard and theyre afraid theyre going to hurt something

Within approved clinical trial settings, the preparation of injectable investigational medicinal products (IMPs) must comply with Good Clinical Practice (GCP), the trial protocol, and local aseptic compounding policies

Multiple factors unrelated to direct medication effects may contribute to respiratory symptoms in patients taking GLP-1 receptor agonists

10.1038/nm.3009